Will deadly Delta Variant boost Pfizer and Moderna's COVID Vaccine Sales?

    Will deadly Delta Variant boost Pfizer and Moderna's COVID Vaccine Sales? These Vaccines Are Actually İn The Best Position To Fight The Alarming Strain Of Coronavirus New dangerous coronavirus variants have already arrived in the US. But unfortunately many believe the worst of the epidemic is over. Unfortunately, the Delta Variant hit India badly. This strain appears to be much more contagious and severe than the others. As a matter of fact, this variant accounts for 10% of new cases in America. COVID-19 vaccine manufacturers could present a huge opportunity to Pfizer PFE (NYSE) $39,24 +0,05 (+%0,13) and Moderna MRNA (NASDAQ) $225,63 +5,49 (+%2,50) How the deadly Delta variant could boost Pfizer and Moderna's COVID-19 vaccine sales. -Some good news Moderna and Pfizer and its partner BioNTech (NASDAQ:BNTX) developed vaccines produced neutralizing antibodies against the Delta variant, according to the results of a laboratory study announced in May. Meeting the demand Decreasing epidemic anxiety in the world may also decrease demand for vaccines. In contrast, President Biden's chief medical adviser, Dr. Anthony Fauci stated that the Delta variant presents the "biggest threat" to the United States in the fight against COVID-19. This threat presents a great opportunity for both Pfizer and Moderna. In the relay race, these 2 vaccines are ahead of their rivals against the deadly variant. Most importantly, while Two Producers announced that they will meet the increasing demand, for example AstraZeneca etc. they hit the wall. The US has announced that it will receive 500 million more doses of Pfizer-BioNTech vaccine to donate to poor countries. Meanwhile, Moderna announced that it has signed an additional 150 million dose vaccine agreement. Getting a boost At one point, Pfizer (along with BioNTech) and Moderna are taking advantage of these additional sales of their respective COVID-19 vaccines. It is the increase in share values ​​that draws the attention of investors. Pfizer shares are up 6%, while Moderna shares are leading the way, up 100%. However, the increase in Delta variant in the coming months will also increase the share values.  

Source: The Motley Fool

 

You may also be interested in:

 

Crypto Law Supported $30 E-Wallet Airdrop. However, Bitcoin Jumped 5%